Alto Neuroscience vs Prime Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patients to drugs using brain biology. 4 data readouts through 2027.
About
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.